These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35222509)

  • 61. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
    Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
    Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
    Llovet JM; Montal R; Villanueva A
    J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction.
    Pathak S; Sonbol MB
    J Hepatocell Carcinoma; 2021; 8():1147-1158. PubMed ID: 34584898
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 66. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence.
    De Luca E; Marino D; Di Maio M
    Cancer Manag Res; 2020; 12():3721-3729. PubMed ID: 32547208
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Current and Future Systemic Therapies for Hepatocellular Carcinoma.
    Bteich F; Di Bisceglie AM
    Gastroenterol Hepatol (N Y); 2019 May; 15(5):266-272. PubMed ID: 31360140
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evolving therapeutic strategies for advanced hepatocellular carcinoma.
    Qureshi A; Michel M; Lerner J; Dasanu CA
    Expert Opin Pharmacother; 2021 Dec; 22(18):2495-2506. PubMed ID: 34252328
    [No Abstract]   [Full Text] [Related]  

  • 70. Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis.
    Sherrow C; Attwood K; Zhou K; Mukherjee S; Iyer R; Fountzilas C
    Liver Cancer; 2020 Sep; 9(5):549-562. PubMed ID: 33083280
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bakouny Z; Assi T; El Rassy E; Nasr F
    J Clin Gastroenterol; 2019 Apr; 53(4):251-261. PubMed ID: 30575632
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 73. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
    Hwang SY; Lee SL; Liu H; Lee SS
    Liver Cancer; 2024 Jun; 13(3):246-255. PubMed ID: 38894810
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Second-line treatment options in hepatocellular carcinoma.
    Marino D; Zichi C; Audisio M; Sperti E; Di Maio M
    Drugs Context; 2019; 8():212577. PubMed ID: 31024634
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
    Kurebayashi Y; Tsujikawa H; Sugimoto K; Yunaiyama D; Araki Y; Saito K; Takahashi H; Kakegawa T; Wada T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Hirata T; Sakamaki K; Kakimi K; Nagao T; Itoi T; Sakamoto M
    Hepatol Res; 2023 Oct; 53(10):1008-1020. PubMed ID: 37300323
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.
    Raoul JL; Frenel JS; Raimbourg J; Gilabert M
    Hepat Oncol; 2019 Jun; 6(1):HEP11. PubMed ID: 31244990
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.
    Hatanaka T; Kakizaki S; Nagashima T; Namikawa M; Ueno T; Tojima H; Takizawa D; Naganuma A; Arai H; Harimoto N; Shirabe K; Uraoka T
    Oncology; 2021; 99(10):641-651. PubMed ID: 34515171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.